Difference between revisions of "Quality"
(expand IHC section) |
|||
Line 26: | Line 26: | ||
**Where did it occur? | **Where did it occur? | ||
*Talk to the clinician. | *Talk to the clinician. | ||
**If it is a ''[[critical diagnosis]]'' contact most-responsible physician immediately... if they are unreachable call physician on-call for the most-responsible physician. | **If it is a ''[[critical diagnosis]]'' contact most-responsible physician immediately... if they are unreachable call physician on-call for the most-responsible physician... if the patient is out-of-town you may have to coordinate with the emergency department. | ||
*Talk to the chief of pathology. | *Talk to the chief of pathology. | ||
*Incident report. | *Incident report. | ||
Line 50: | Line 50: | ||
*Filing problem. | *Filing problem. | ||
*Interpretation of report problem (poorly written, bad interpretation). | *Interpretation of report problem (poorly written, bad interpretation). | ||
==Error reduction== | ==Error reduction== | ||
Line 88: | Line 81: | ||
==Immunohistochemistry== | ==Immunohistochemistry== | ||
{{Main|Immunohistochemistry}} | {{Main|Immunohistochemistry}} | ||
Work-up of suspected IHC problems: | |||
*Review controls (internal and external). | |||
**Isolated to case vs. larger problem? | |||
***Discuss with lab/make other pathologists of the issue. | |||
*Repeat test - to identify the cause. | |||
IHC process: | |||
#Ischemia time - warm ischemia, preparation of specimen. | |||
#Fixation - under, over, defective fixative, not enough fixative. | |||
#Processing prior to antibody binding, usu. heating (antigen retrieval). | |||
#Antibody-antigen binding. | |||
#Reporter molecule binding. | |||
#Counterstaining. | |||
#Interpretation. | |||
Notes: | |||
*Problems can arise at any step. | |||
===Classification of IHC tests=== | |||
IHC tests are classified in a paper by Torlakovic ''et al.'':<ref name=pmid20154273>{{Cite journal | last1 = Torlakovic | first1 = EE. | last2 = Riddell | first2 = R. | last3 = Banerjee | first3 = D. | last4 = El-Zimaity | first4 = H. | last5 = Pilavdzic | first5 = D. | last6 = Dawe | first6 = P. | last7 = Magliocco | first7 = A. | last8 = Barnes | first8 = P. | last9 = Berendt | first9 = R. | title = Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. | journal = Am J Clin Pathol | volume = 133 | issue = 3 | pages = 354-65 | month = Mar | year = 2010 | doi = 10.1309/AJCPDYZ1XMF4HJWK | PMID = 20154273 }}</ref> | |||
*''Class I'': | *''Class I'': | ||
**Adjunct to histomorphology. | **Adjunct to histomorphology. | ||
Line 96: | Line 109: | ||
**Used directly for treatment decisions. | **Used directly for treatment decisions. | ||
**Examples: ER, PR, HER2. | **Examples: ER, PR, HER2. | ||
The implication of irregularies in the different classes are different. Problems in ''Class II'' tests are potentially more severe, as there is no internal control. | |||
==See also== | ==See also== |
Revision as of 15:06, 22 January 2012
Quality, in pathology, has got a lot of attention lately because there have been high profile screw-ups that lead to significant harm.[1]
Analysis
Overview
Quality issues are examined a number of different ways, e.g. root cause analysis, failure mode and effects analysis (FMEA).
A common way to break down error analysis is:
Errors in pathology | |||||||||||||||||||||||||||||||||
Pre-analytical errors | Analytical errors | Post-analytical errors | |||||||||||||||||||||||||||||||
Failure-potential analysis
Adapted from Ullman:[2]
- Identify potential individual failures.
- Identify the consequences of those failures.
- Identify how the individual failures can arise.
- Identify the corrective action.
General error analysis
- Pathology errors happen any time from when the lab gets the specimen until after the report is issued.
When errors happen:
- Work-up problem.
- Where did it occur?
- Talk to the clinician.
- If it is a critical diagnosis contact most-responsible physician immediately... if they are unreachable call physician on-call for the most-responsible physician... if the patient is out-of-town you may have to coordinate with the emergency department.
- Talk to the chief of pathology.
- Incident report.
- Reconstruct error.
- Was it a specimen mix-up?
- Is there another error?
- Was it a specimen mix-up?
- Amend report(s).
- Remedy source of error.
Pre-analytic errors
- Container mix-up - pre-lab & in-lab.
- Block mix-up.
- Slide mix-up - labels wrong.
- Poor quality slides (fixation, processing, staining).
Analytic errors
- Interpretation wrong.
- Difficult case.
- Technical factors (quality of slides).
Post-analytic errors
- Wrong case signed-out.
- Filing problem.
- Interpretation of report problem (poorly written, bad interpretation).
Error reduction
Various strategies can be employed:[3]
- Training of staff - on error handling.
- Computer order entry.
- Avoid duplication fatigue.
- Quick correlation with several identifying features.
- Full name, sex, date of birth -- these all appear when one opens a case.
- Barcode use.
- Avoid transcription errors.
- Clinical information entry required.
- Allow correlation with test.
- The interpretation may differ if the history says "screening coloscopy" versus "large cecal mass, anemia and weight loss".
- Allow correlation with test.
Other strategies:
- Statistical process control.
Sources of error
- "Human error".
- Training.
- Work flow.
- Process gaps.
- Process control.
- Lack of redundancy.
Biopsy size
Very small tissue fragments are associated with a decreased diagnostic yield and an increased diagnostic uncertainty.
Immunohistochemistry
Work-up of suspected IHC problems:
- Review controls (internal and external).
- Isolated to case vs. larger problem?
- Discuss with lab/make other pathologists of the issue.
- Isolated to case vs. larger problem?
- Repeat test - to identify the cause.
IHC process:
- Ischemia time - warm ischemia, preparation of specimen.
- Fixation - under, over, defective fixative, not enough fixative.
- Processing prior to antibody binding, usu. heating (antigen retrieval).
- Antibody-antigen binding.
- Reporter molecule binding.
- Counterstaining.
- Interpretation.
Notes:
- Problems can arise at any step.
Classification of IHC tests
IHC tests are classified in a paper by Torlakovic et al.:[4]
- Class I:
- Adjunct to histomorphology.
- Examples: CD45, S-100.
- Class II:
- Considered independent of the other information in the pathology report; thus, cannot be derived from other information in the report.
- Used directly for treatment decisions.
- Examples: ER, PR, HER2.
The implication of irregularies in the different classes are different. Problems in Class II tests are potentially more severe, as there is no internal control.
See also
References
- ↑ URL: http://www.attorneygeneral.jus.gov.on.ca/inquiries/goudge/index.html. Accessed on: 1 March 2011.
- ↑ Ullman, David G. (1997). The mechanical design process. Toronto: McGraw-Hill Companies Inc.. ISBN 0-07-065756-4.
- ↑ Fabbretti, G. (Jun 2010). "Risk management: correct patient and specimen identification in a surgical pathology laboratory. The experience of Infermi Hospital, Rimini, Italy.". Pathologica 102 (3): 96-101. PMID 21171512.
- ↑ Torlakovic, EE.; Riddell, R.; Banerjee, D.; El-Zimaity, H.; Pilavdzic, D.; Dawe, P.; Magliocco, A.; Barnes, P. et al. (Mar 2010). "Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.". Am J Clin Pathol 133 (3): 354-65. doi:10.1309/AJCPDYZ1XMF4HJWK. PMID 20154273.